Mindmed reports 2023 financial results and business updates

New york--(business wire)---- $mnmd--mind medicine (mindmed) inc. (nasdaq:mnmd), (cboe canada:mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended december 31, 2023 and provided a business update. “2023 was a highly productive year for mindmed, which concluded with positive phase 2b results for mm120 in the treatment of adult patients with gad,” said rob.
MNMD Ratings Summary
MNMD Quant Ranking